{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:20:05Z","timestamp":1778332805906,"version":"3.51.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The objective of this research is to examine the therapy and outlook of pediatric primary central nervous system Burkitt lymphomas.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study involves a retrospective analysis of the clinical data of a child with primary central nervous system Burkitt lymphoma who underwent treatment in our department. In addition, pertinent literature was reviewed to provide a comprehensive understanding of the topic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The patient was admitted to the neurosurgery department with symptoms of headache and vomiting. Brain magnetic resonance imaging (MRI) revealed multiple lesions in the right frontal and temporal lobes, dorsal thalamus, and posterior medulla oblongata. Most of the tumor mass was surgically removed from the right ventricle and diagnosed as Burkitt lymphoma. Abnormal lymph nodes were not found outside of the central nervous system. The patient achieved complete remission (CR) after receiving 6 cycles of treatment (R-AA-BB-CC-AA-BB-CC) based on the regimen of the Southern Pediatric Non-Hodgkin Lymphoma Treatment Collaboration Group 2017. As of November 23, 2023, the patient remained alive with no evidence of recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Primary central nervous system Burkitt lymphoma is rare in children, and there is no universally accepted treatment protocol. However, the regimen outlined by the South China Children\u2019s Cancer Group-Non-Hodgkin Lymphoma in 2017 (SCCCG-NHL-2017) can serve as a useful reference for treating pediatric non-Hodgkin lymphoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002944","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T10:02:40Z","timestamp":1727344960000},"page":"375-379","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Primary Central Nervous System Burkitt\u2019s Lymphoma in a Pediatric Patient: A Case Report and Literature Review"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9648-3144","authenticated-orcid":false,"given":"Jian","family":"Zhao","sequence":"first","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Arian","family":"Hassani","sequence":"additional","affiliation":[{"name":"Hematology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincheng","family":"Song","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"Suppl_1","key":"R1-20250804","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10428190802311441","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment","volume":"49","author":"Rubenstein","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bjh.14074","article-title":"Adolescent and young adult non-Hodgkin lymphoma","volume":"173","author":"Hochberg","year":"2016","journal-title":"Br J Haematol"},{"key":"R4-20250804","first-page":"397","article-title":"Non-Hodgkin\u2019s lymphoma with central nervous system abnormality as initial symptom: a case report and literature review","volume":"24","author":"Zhang","year":"2017","journal-title":"Chinese Pediatr Emerg Med"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2019001062","article-title":"Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents","volume":"3","author":"Attarbaschi","year":"2019","journal-title":"Blood Adv"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pbc.20736","article-title":"A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation","volume":"47","author":"Abla","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1078-0432.CCR-10-1161","article-title":"Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"17","author":"Abla","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/asheducation-2016.1.386","article-title":"Management of primary central nervous system lymphoma in children","volume":"2016","author":"Roth","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium","volume":"16","author":"Chan","year":"2011","journal-title":"Oncologist"},{"key":"R10-20250804","first-page":"415","article-title":"Diagnosis of primary central nervous system lymphoma: a systematic review of CSF screening and the role of early brain biopsy","volume":"6","author":"Morell","year":"2019","journal-title":"Neurooncol Pract"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.wneu.2018.01.033","article-title":"Intraoperative flow cytometry enables the differentiation of primary central nervous system lymphoma from glioblastoma","volume":"112","author":"Koriyama","year":"2018","journal-title":"World Neurosurg"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","article-title":"High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma","volume":"83","author":"Holdhoff","year":"2014","journal-title":"Neurology"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trail","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemo-immunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRi regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/neuonc\/nos159","article-title":"Surgery for primary CNS lymphoma challenging a paradigm","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro Oncol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective proof of concept phase II study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/asheducation-2017.1.556","article-title":"Biology of CNS lymphona and the potential of noval agents","volume":"2017","author":"Rubenstein","year":"2017","journal-title":"Hematology"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lympho","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:02:08Z","timestamp":1754337728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002944","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,26]]},"assertion":[{"value":"2023-07-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}